TORONTO, ON, CANADA (August 2, 2017)- Cyclica Inc. is pleased to announce that it has added Dr. Nancy Levy as Executive Director, Business Development.
Nancy Levy joins the management team after spending 1.5 years advising management on business development strategies. Nancy obtained her PhD in Microbiology and Immunology from the University of Chicago, after which she spent 20 years in various roles within the industry including: Marketing Manager/Clinical Program Manager at Genzyme, CEO of Immunetics, Strategic Development Consultant for Phase II product at Millennium Pharmaceuticals, and currently Managing Partner at BioHealth Management and Bostonlanding.us.
Naheed Kurji, Cyclica’s President and CEO, had this to say, “I have known Nancy for the past 2 years, and over the course of those years she has provided me and the Cyclica team with valuable support in entering the US marketplace. Nancy is one of the most well respected, thoughtful, and supportive people that I have gotten to know, and it is our privilege to have her join us on our journey. With Nancy based out of Cambridge, MA, we will have a presence in a strategic geography to drive our growth.”
Nancy had this to say about her appointment, “I’ve been advising senior management, and closely following Cyclica’s progress for the past 2 years. Over that period, they have enhanced their core team, refined their strategy, and are focused on the right things. Their value proposition addresses key needs in the pharmaceutical and related industries, and I believe they are well positioned for broad adoption. I am excited to be part of this journey, and to support Cyclica’s business development growth.
— 30 —
Cyclica Inc. has developed, validated and patented a structure-based proteome-wide screening platform, Ligand Express™, that currently features PROBEx (proteome-screening), SWITCHx (ligand effect prediction) and DIVEx (systems biology & drug-protein interactomes). Ligand Express™ is unique in that it is a drug-centric platform. For a small molecule ligand, Ligand Express™ automatically generates an intelligent list of ligand-protein interactions by searching through a large proprietary database of all available structurally-characterized proteins. The platform provides a panoramic view of a small molecule ligand to better understand on- and off-target interactions, and is valuable in finding novel desirable or undesirable targets. By gaining insights into a ligand’s polypharmacology, Cyclica’s clients can identify unknown targets, prioritize lead candidates, elucidate adverse effects, and understand repurposing opportunities. www.cyclicarx.com